Bone augmentation by onlay implant using recombinant human BMP-2 and collagen on adult rat skull without periosteum.
The purpose of this study was to determine whether bone augmentation could be obtained by the composite of recombinant human bone morphogenetic protein-2 (rhBMP-2) and bioabsorbable atelocollagen when the periosteum was resected, and to compare the efficacy of the rhBMP-2/collagen implant and the collagen alone implant. The onlay implant was inserted into the space between the elevated galea aponeurotica and the skull without the periosteum of 10-month-old rats. The rhBMP-2/collagen implant resulted in osteoblasts differentiation under the galea at 1 week and active bone formation without a prior formation of cartilage. At 4 weeks, the bony trabeculae were interconnected and connected directly with the compact bone of the skull. Histomorphometric analysis at 4 weeks demonstrated that the rhBMP-2/collagen implant showed 92.5% in the volume of bone tissue, whereas the collagen alone showed 0%. The implanted collagen was gradually replaced by bone tissue in the presence of rhBMP-2. Our present results indicate that rhBMP-2 stimulates undifferentiated mesenchymal cells in the galea overlying the implant to proliferate and differentiate directly into osteoblasts on the carrier collagen fibers. The collagen matrix was stably placed on the skull and suitable as a substitute for rhBMP-2. The rhBMP-2/collagen onlay implant might be clinically applicable for bone augmentation even under the condition without the periosteum.
Murata
M
M
Second Department of Oral Surgery, School of Dentistry, Health Sciences University of Hokkaido, Tobetsu, Hokkaido, Japan. murata@hoku-iryo-u.ac.jp
Maki
F
F
Sato
D
D
Shibata
T
T
Arisue
M
M
D020341:Absorbable Implants; D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D003094:Collagen / Q000627:therapeutic use*; D004337:Drug Carriers; D005205:Fascia; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008648:Mesoderm / Q000166:cytology / Q000502:physiology; D010006:Osteoblasts / Q000473:pathology; D010012:Osteogenesis / Q000502:physiology; D010521:Periosteum / Q000601:surgery; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D012886:Skull / Q000473:pathology / Q000601:surgery*; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C059821:atelocollagen; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen